Mostrar el registro sencillo del ítem

dc.contributor.authorGarcía-García, María Luz
dc.contributor.authorCalvo, Cristina
dc.contributor.authorMoreira, Ana
dc.contributor.authorCañas, José Antonio
dc.contributor.authorPozo Sanchez, Francisco 
dc.contributor.authorSastre, Beatriz
dc.contributor.authorQuevedo, Sergio
dc.contributor.authorCasas Flecha, Inmaculada 
dc.contributor.authorDel Pozo, Victoria
dc.date.accessioned2019-03-19T15:24:05Z
dc.date.available2019-03-19T15:24:05Z
dc.date.issued2017-05
dc.identifier.citationMedicine (Baltimore). 2017 May; 96(18): e6787.es_ES
dc.identifier.issn0025-7974es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7357
dc.description.abstractMuch attention has recently been focused on thymic stromal lymphopoietin (TSLP), IL-33, and periostin in allergic disease, but less is known about their role in viral bronchiolitis.The aim of the study was to investigate whether infants exhibit enhanced nasal airway secretion of TSLP, IL-33, and periostin during natural respiratory viral bronchiolitis compared to healthy controls.In total, 213 infants < 2 years of age, hospitalized with bronchiolitis from October/2013 to April/2016 were enrolled alongside 45 healthy infants. Nasopharyngeal aspirates (NPA) were screened for respiratory viruses by the polymerase chain reaction. TSLP, IL-33, and periostin were measured in NPAs. Clinical data were recorded.At least 1 virus was detected in 186 (87.3%) hospitalized infants: 149 (70%) respiratory syncytial virus (RSV); 42 (19.7%) rhinovirus (HRV); 16 (7.5%) parainfluenza virus (PIV); 9 (4.2%) adenovirus; 10 (4.7%) bocavirus; and 7 (3.3%) metapneumovirus (hMPV). Infants with bronchiolitis had higher levels of TSLP (P = .02), IL-33 (P<.001), and periostin (P = .003) than healthy controls.Detectable levels of TSLP and periostin were more frequent in virus-positive than in virus-negative patients (P = .05). TSLP and IL-33 were also more common in coinfections, mainly RSV and HRV, than in single-infections (P < .05). No patient with bronchiolitis but with negative viral detection had detectable levels of nasal TSLP or IL-33. Infants with hospital stay ≥5 days were more likely to have detectable levels of nasal TSLP and periostin after adjusting by age (P = .01). Bronchiolitis by common respiratory viruses is associated with elevated nasal levels of TSLP, IL-33, and periostin, factors known to be important in the development of Th2-response. Respiratory viruses in early life might shift immune responses toward Th2, involving asthma, and allergic diseases.es_ES
dc.description.sponsorshipThis study has been partially supported by FIS (Fondo deInvestigaciones Sanitarias—Spanish Health Research Fund) Grants PI12/0129 and FEDER (Fondo Europeo de Desarrollo Regional); Alfonso X El Sabio,University Grant: VI Convocatoria Santander-UAX; CIBER de EnfermedadesRespiratorias (CIBERES), a Carlos III Institute of Health Initiativees_ES
dc.language.isoenges_ES
dc.publisherWolters Kluwer es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nd/4.0/*
dc.subjectAsthmaes_ES
dc.subjectBronchiolitises_ES
dc.subjectIL-33es_ES
dc.subjectInfantses_ES
dc.subjectPeriostines_ES
dc.subjectRespiratory viruseses_ES
dc.subjectTh2es_ES
dc.subjectTSLPes_ES
dc.subject.meshBronchiolitis, Viral es_ES
dc.subject.meshCell Adhesion Molecules es_ES
dc.subject.meshCross-Sectional Studies es_ES
dc.subject.meshCytokines es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHospitalization es_ES
dc.subject.meshHumans es_ES
dc.subject.meshInfant es_ES
dc.subject.meshInterferon-gamma es_ES
dc.subject.meshInterleukin-10 es_ES
dc.subject.meshInterleukin-33 es_ES
dc.subject.meshMale es_ES
dc.subject.meshNasopharynx es_ES
dc.subject.meshPolymerase Chain Reaction es_ES
dc.subject.meshProspective Studies es_ES
dc.subject.meshSeverity of Illness Index es_ES
dc.titleThymic stromal lymphopoietin, IL-33, and periostin in hospitalized infants with viral bronchiolitises_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID28471975es_ES
dc.format.volume96es_ES
dc.format.number18es_ES
dc.format.pagee6787es_ES
dc.identifier.doi10.1097/MD.0000000000006787es_ES
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.contributor.funderAlfonso X el Sabio University (España) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1536-5964es_ES
dc.relation.publisherversionhttps://doi.org/10.1097/MD.0000000000006787es_ES
dc.identifier.journalMedicine (Baltimore)es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI12/0129es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoDerivatives 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución-NoDerivatives 4.0 Internacional